Autoantibodies to tumor-associated antigens in breast carcinoma

Benjamin Piura, Ettie Piura

    Research output: Contribution to journalReview articlepeer-review

    37 Scopus citations


    Autoantibodies (AAbs) to tumor-associated antigens (TAAs) have been identified in the circulation of patients with cancer. This paper will focus on recent knowledge related to circulating AAbs to TAAs in breast carcinoma. So far, the following TAAs have been identified to elicit circulating AAbs in breast carcinoma: p53, MUC-1, heat shock proteins (HSP-27, HSP-60, and HSP-90), HER2/neu/c-erb B2, GIPC-1, c-myc, c-myb, cancer-testis antigens (NY-ESO-1), BRCA1, BRCA2, endostatin, lipophilin B, cyclin B1, cyclin D1, fibulin, insulin-like growth factor binding protein 2 (IGFBP-2), topoisomerase II alpha (TOPO2α), and cathepsin D. Measurement of serum AAbs to one specific TAA only is of little value for screening and early diagnosis of breast carcinoma; however, assessment of AAbs to a panel of TAAs may have promising diagnostic potential.

    Original languageEnglish
    Article number264926
    JournalJournal of Oncology
    StatePublished - 1 Dec 2010

    ASJC Scopus subject areas

    • Oncology


    Dive into the research topics of 'Autoantibodies to tumor-associated antigens in breast carcinoma'. Together they form a unique fingerprint.

    Cite this